Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Nanomedicine, an interdisciplinary field merging the power of nanotechnology with the intricacies of medicine, has revolutionized healthcare on a scale previously unimaginable. By manipulating ...
Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Identify research insights to guide ...
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...
LONDON (MarketWatch) -- Privately held San Francisco drug company Synosis Therapeutics has agreed to buy five central nervous system drugs, including four phase 1 molecules, from Switzerland's Roche ...
GLP-1 receptors are present throughout the brain and can contribute to a wide range of behaviors and conditions. (Drucker, Rinaman, Secher) Research is ongoing into which parts of the brain are ...
According to the collaboration agreement, the two parties will combine Insilico Medicine’s validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS’s ...
Overall Count and Share for 'Central Nervous System Drug Key Laboratory of Sichuan Province' based on the 12-month time frame mentioned above. Note: Articles may be assigned to more than one subject ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results